Information Provided By:
Fly News Breaks for April 3, 2017
UTHR
Apr 3, 2017 | 15:39 EDT
As previously reported, Cowen analyst Chris Shibutani downgraded United Therapeutics to Market Perform from Outperform, saying the delay in the planned U.S. launch of the RemoSynch system for Remodulin removes a key near-term catalyst and also impacts an avenue he thought the company could use to temper the rate of Remodulin revenue erosion he sees starting in 2019. Shibutani lowered his price target on United Therapeutics to $121 from $140.
News For UTHR From the Last 2 Days
There are no results for your query UTHR
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.